Skip to content

Early detection of exacerbations in mucociliary clearance diseases.

Early detection of pulmonary exacerbations in mucociliary clearance diseases: Molecular fingerprinting by exhaled breath and microbiome analysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26275
Enrollment
100
Registered
2012-09-18
Start date
2012-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis Primary Ciliary Dyskinesia

Interventions

Longitudinal observational study during one year with collection of 5 exhaled breath and microbiology samples.

Sponsors

Dept. Respiratory Medicine Academic Medical Centre, University of Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. CF diagnosis is based on: clinical symptoms in combination with an abnormal sweat test (chloride > 60 mmol/l) and/or identification of mutations in both alleles of the CFTR gene; 2. PCD diagnosis is based on: A combination of clinical symptoms, abnormal movement of cilia on microscopic evaluation of respiratory epithelial biopsies and epithelial cell cultures, or identification of an ultra structural defect in the cilia by electron microscopy; 3. ≥ 6 years of age; 4. Stable respiratory disease for at least 6 weeks ( as determined by the treating physician); 5. Ability to perform lung function measurement.

Exclusion criteria

Exclusion criteria: 1. Mental retardation; 2. Diabetes Mellitus (CF complication); 3. Technical unsatisfactory performance of measurements; 4. On the waiting list for lung transplantation; 5. Participation in the PREVEC or VERTEX study (AMC).

Design outcomes

Primary

MeasureTime frame
1. Relative changes in electronic nose sensors; 2. Retention time; 3. Abundance and mass to charge ratio from GC-MS analysis.

Secondary

MeasureTime frame
(Change in) bacterial and viral diversity.

Contacts

Public ContactT. Paff

Postbus 7057

t.paff@vumc.nl+31 (0)20 4445491

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)